Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
NCT ID: NCT00396448
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1253 participants
INTERVENTIONAL
2007-02-28
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CP-945,598 Treatment B
CP-945,598 Treatment B
Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
CP-945,598 Treatment A
CP-945,598 Treatment A
Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Placebo
Placebo
Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-945,598 Treatment B
Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
CP-945,598 Treatment A
Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Placebo
Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Diabetes
* Adults with serious or unstable current or past medical conditions
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Peoria, Arizona, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Farmington Hills, Michigan, United States
Pfizer Investigational Site
Cary, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Wilmington, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Anderson, South Carolina, United States
Pfizer Investigational Site
Johnson City, Tennessee, United States
Pfizer Investigational Site
Bountiful, Utah, United States
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina
Pfizer Investigational Site
Ramos Mejía, Buenos Aires, Argentina
Pfizer Investigational Site
Córdoba, Córdoba Province, Argentina
Pfizer Investigational Site
Villa Carlos Paz, Córdoba Province, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Capital Federal, , Argentina
Pfizer Investigational Site
Caringbah, New South Wales, Australia
Pfizer Investigational Site
Miranda, New South Wales, Australia
Pfizer Investigational Site
Wollongong, New South Wales, Australia
Pfizer Investigational Site
Caboolture, Queensland, Australia
Pfizer Investigational Site
Kippa-Ring, Queensland, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Armentières, , France
Pfizer Investigational Site
Lorient, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Poitiers, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Frankfurt am Main, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Mannheim, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
San Luis Potosí City, San Luis Potosí, Mexico
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Uppsala, , Sweden
Pfizer Investigational Site
Watford, Herts, United Kingdom
Pfizer Investigational Site
Warminster, Wiltshire, United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Luton, , United Kingdom
Pfizer Investigational Site
Northwood, Middlesex, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5351019
Identifier Type: -
Identifier Source: org_study_id